Conduit Pharmaceuticals Gets Patent for Lead Autoimmune Drug

Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a company specializing in developing innovative drug solutions, recently announced the successful approval of a composition of matter patent application by IP Australia for its lead asset, an HK-4 Glucokinase Activator. This patent is a significant milestone for Conduit Pharmaceuticals as it targets a variety of autoimmune diseases and marks a substantial achievement in their intellectual property portfolio.

The company is set to participate in the Patent Prosecution Highway (PPH) program, designed to expedite patent examination processes in key markets such as the U.S., Europe, and Japan. The approval from IP Australia, designated as patent application 2022384750, increases the likelihood of obtaining similar approvals in these crucial jurisdictions. Securing patents in these major markets is particularly valuable, providing up to 20 years of protection for marketed drug products.

Conduit's research and development team employed advanced solid-form technology to identify cocrystals of their lead asset, AZD1656, another HK-4 Glucokinase Activator. These cocrystals are noteworthy for their potential in treating a broad spectrum of autoimmune conditions. Jeffrey A. Lindeman, Ph.D., a consultant on cocrystal intellectual property for the company, emphasized that the creation of these cocrystals and securing patent protection for them highlights Conduit’s scientific expertise and strategic approach to drug development.

Cocrystal patents are listed as "drug substance" patents in the U.S. Food and Drug Administration’s (FDA) Orange Book. These patents not only expand Conduit's intellectual property assets but also enhance the company's potential for future out-licensing opportunities, adding significant strategic value within the pharmaceutical industry.

Dr. David Tapolczay, Chief Executive Officer of Conduit, remarked, "The approval of the composition of matter patent in Australia for our lead asset underscores our dedication to optimizing our intellectual property portfolio." He noted that with up to 20 years of patent protection now secured, the patent validates the company's robust internal R&D capabilities and strengthens their position for future out-licensing opportunities.

Conduit Pharmaceuticals has crafted a unique business model aimed at delivering medications to patients by addressing unmet medical needs while extending the intellectual property for their existing assets through cutting-edge solid-form technology. They then commercialize these products in partnership with other life science companies. The company is led by a seasoned team of pharmaceutical executives including CEO Dr. David Tapolczay, formerly CEO of the UK-based medical research charity LifeArc, and Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, Inc., who serves as the Chair of Conduit's Board.

The company's pipeline is Phase II ready, featuring a HK4 Glucokinase Activator that targets autoimmune diseases and has undergone over 20 clinical trials involving more than 1,000 patients. Additionally, they are developing an MPO Inhibitor, which is believed to have the potential for treating Idiopathic Male Infertility.

Conduit Pharmaceuticals' strategic initiatives and recent patent approval demonstrate their commitment to advancing medical science and providing innovative solutions in the pharmaceutical industry. These efforts not only enhance their market position but also underscore their potential for future growth and success in addressing critical healthcare needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!